Bladder Cancer
An Introduction to Bladder Cancer
Bladder cancer is the most common malignancy involving the urinary system. While cisplatin-based chemotherapy and Bacillus Calmette-Guérin (BCG) remains the standard of care for muscle-invasive and non-muscle-invasive disease, respectively, the development of immune checkpoint inhibitors has transformed the management of advanced urothelial cancer, with atezolizumab, durvalumab and avelumab being approved for use following platinum-based chemotherapy or in as first-line treatment in platinum-ineligible patients. However, many patients fail to respond to these agents, and predictive biomarkers remain an unmet need. Emerging treatment options include combined immunotherapy approaches, targeted therapies and antibody-drug conjugates.
Browse our selection of video highlights and short articles from the conference hub, which provide insights into the latest updates from major conferences, and a collection of peer-reviewed articles from the journal portfolio. These are complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Our supporting partners do not constitute an endorsement of the content on this page.
How might new treatment combinations and emerging biomarkers inform bladder cancer management? Five studies selected from ESMO 2026 address this question across different disease settings: VOLGA, KEYNOTE-B15/EV-304, ENERGIZE, KEYNOTE-866 and POTOMAC. Their findings examine perioperative treatment intensification, the potential of circulating tumor DNA (ctDNA) to characterize treatment response and the addition of immunotherapy to bacillus Calmette–Guérin (BCG) in high-risk non-muscle-invasive disease.
It is with great pleasure that we present the latest edition of touchREVIEWS in Oncology & Haematology. This issue reflects the growing momentum of precision oncology, from liquid biopsy and response-adapted strategies to antibody–drug conjugates (ADCs) and immune-based therapies, ...
With the European Society for Medical Oncology (ESMO) Congress 2026 fast approaching, attention is turning to Madrid, where the meeting is held from 23–27th October. Whether you are joining onsite or via the virtual platform, the three Presidential Symposia are the sessions not to miss. This year they carry 12 late-breaking abstracts (LBAs) spanning melanoma, lung, genitourinary, gastrointestinal, gynecological and rare cancers. With close to 300 scientific and educational sessions to choose from, we know the programme can feel overwhelming. So we have put together a quick guide to the headline sessions: when and where they run, who is presenting, and links to explore each one in the programme planner, so you can decide which to prioritize.
The European Society for Medical Oncology (ESMO) Congress 2026 promises a compelling program of clinical data, spanning personalized cancer vaccines, next-generation antibody–drug conjugates (ADCs) and novel approaches to targeted therapy and immunotherapy. With several studies already generating excitement following positive topline announcements, all eyes will be on the full results and their potential implications for clinical practice. Below, we highlight the 12 presidential abstracts to watch, the key findings to look out for and the questions these studies could help answer.
Urothelial carcinoma (UC) is the 11th most common cancer in the UK, with approximately 11,000 new bladder cancer diagnoses annually.1 Globally, bladder cancer accounts for approximately 635,000 new diagnoses and 228,000 deaths annually, based on the latest GLOBOCAN estimates for 2024.2 Bladder cancer constitutes ...
Join us as leading experts discuss key data from the Plenary, Late-breaking and top oral sessions across each major disease area at ASCO 2026 touchONCOLOGY coverage of ASCO 2026 2026 American Society of Clinical Oncology (ASCO) Annual Meeting brought together the global oncology ...
Bladder cancer’s treatment landscape is changing fast; and the biggest abstracts presented at ASCO 2026 show just how far that shift now extends. With insight from our Editor-in-Chief, Prof Axel S Merseburger (University Hospital Schleswig-Holstein, Germany), we examine the four studies likely to have the biggest impact on clinical practice across advanced and localized disease: EV-302, KEYNOTE-905, SAKK 06/19 and POTOMAC.
See who the oncology community selected as the rising stars of 2026!
In this Future Leaders interview, Dr Kevin Keane discusses the mentors who shaped his approach to clinically meaningful research, the integration of surgery and innovation in uro-oncology and the collaborative, patient-centred advances set to transform bladder cancer care.
At EAU26, Dr Kevin Keane presented early results from the G-DISCO trial, the first-in-human study exploring a streamlined intravesical approach for patients with BCG-unresponsive non–muscle-invasive bladder cancer.
At #EAU26, Professor Dickon Hayne presented early findings from the ZiPUP study. This is a phase I trial exploring a novel PET imaging approach in urothelial cancer. In this interview, he discusses the unmet need in staging, the study’s design and what the preliminary data might mean for clinical practice.
At EAU26, Prof Dickon Hayne presented findings from the ANZUP 1301 (BCG+MM) trial. With global BCG shortages and ongoing challenges around tolerability, the study offers timely insights into how combination intravesical strategies may deliver comparable efficacy while improving patient experience and resource utilisation.
At the recent 2026 ASCO Genitourinary Cancers Symposium (ASCO GU26), Dr Jeannie Hoffman-Censits (The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Center, Baltimore, MD, USA) presented data from ECOG-ACRIN EA8192 cohort C, exploring a new approach for patients with high-grade (HG) upper tract urothelial carcinoma (UTUC) who are ineligible for cisplatin. With neoadjuvant options limited in this population, the trial assessed whether combining chemotherapy with immunotherapy could improve outcomes.
The 2026 ASCO Genitourinary Cancers Symposium showcased pivotal advances across renal, prostate and bladder cancers. Key late-breaking trials across kidney, prostate and bladder cancer highlighted promising combinations, novel targeted therapies and innovative radioligand approaches, demonstrating improved disease control, progression-free survival and ...
2025 has brought exciting developments in oncology, with groundbreaking research and real-world progress showcased at ASCO, ESMO, EHA, ASH and many more leading conferences around the world. We asked our key faculty to share what they believe has been most impactful so far this year – here’s what they told us.
The European Society for Medical Oncology (ESMO) 2025 congress brought over 100 late-breaking abstracts, 250 sessions, 600 expert speakers and 33,800 delegates to Berlin in October. The meeting highlighted innovations ranging from novel agents to real-world evidence and patient-centred care. In this article, hear from the experts on the key breakthroughs and clinical insights set to shape the future of oncology practice.
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
